Accessibility Menu
Biomerica logo

Biomerica(NASDAQ) BMRA

Current Price$1.66
Market Cap$4.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1983)-98%
5 Year-95%
1 Year-62%
1 Month-9%
Biomerica last closing stock price
MetricPriceDate
Last closeUSD 1.592026-07-24
Biomerica stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.79%USD 1.612026-07-17
1 month-9.43%USD 1.752026-06-24
3 month-25.93%USD 2.142026-04-24
Year to date-37.1%USD 2.522025-12-31
1 year-61.71%USD 4.142025-07-24
3 year-85.85%USD 11.202023-07-25
5 year-94.6%USD 29.362021-07-23
Since inception-98.24%USD 90.001983-08-23

Biomerica Financials at a Glance

Market Cap

$4.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.33M

Net Income (TTM)

-$4.17M

EPS (TTM)

-$1.50

P/E Ratio

-1.06

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$1.66

Volume

17,386.803

Open

$1.61

Previous Close

$1.59

Daily Range

$1.58 - $1.63

52-Week Range

$1.57 - $4.60

Estimated Earnings Date

Aug 27, 2026

BMRA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biomerica

Biomerica makes medical test kits that help doctors diagnose digestive and food-related problems. Its products let people and clinics quickly check for specific health issues using blood or stool samples. These tests help patients and doctors find causes of symptoms and guide treatment choices.

Products and Services

  • Contract Manufacturing (approximately 14% of revenue for the three months ended August 31, 2025): Produces diagnostic kits for other companies and partners.
  • Over-the-Counter (OTC) Tests (approximately 12% of revenue for the three months ended August 31, 2025): Home-use kits sold in drugstores and online for self-testing.
  • inFoods IBS Platform: Blood test to identify foods that trigger irritable bowel syndrome symptoms.
  • hp+detect: FDA-cleared test for Helicobacter pylori, a bacteria recognized as a risk factor for gastric cancer.
  • COVID-19 Diagnostics: Tests for detecting COVID-19 infection, sold to clinics and labs.

Growth and Expansion

  • Launched inFoods IBS product to U.S. gastrointestinal doctors in 2024.
  • Received FDA clearance for hp+detect in December 2023 and began U.S. sales.
  • Expanded international sales to Asia, Europe, Middle East, and South America since 2023.
  • Raised $912,000 in fiscal Q1 2026 (quarter ended August 31, 2025) through an equity offering to support operations.
  • Implemented cost-cutting and workforce reduction in July 2024 to manage cash flow.

What Makes Biomerica Stand Out

Biomerica sells its products worldwide, with approximately 49% of Q1 2026 net sales in Asia.

Its focus on diagnostic-guided therapy helps doctors tailor treatments for digestive issues. The company uses multiple sales channels, including labs, clinics, and retail stores, to reach diverse customers.

Five Things You Need to Know

  • Net sales were $1.38 million in Q1 2026, down 24% year-over-year.
  • Gross profit was $424,000 in Q1 2026, up 47% from Q1 2025.
  • Operating loss improved to $1.12 million in Q1 2026, down from $1.37 million.
  • Cash used in operations was $268,000 in Q1 2026, an 80% improvement.
  • One Asian customer made up 48% of Q1 2026 sales, showing high customer concentration.

Bottom Line

Biomerica has adapted by launching new products and expanding globally, but faces ongoing financial and operational challenges. Its focus on targeted diagnostics and cost control shapes its current strategy.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

54

CEO

Zackary S. Irani

Website

www.biomerica.com

Headquarters

Irvine, CA 92614, US

BMRA Financials

Key Financial Metrics (TTM)

Gross Margin

4.32%

Operating Margin

-123.74%

Net Income Margin

-96.49%

Return on Equity

-98.14%

Return on Capital

-112.58%

Return on Assets

-85.57%

Earnings Yield

-94.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.09M

Volume

17.39K

Avg. Volume

15.09K

Financials (TTM)

Gross Profit

$187.00K

Operating Income

-$5.35M

EBITDA

-$3.74M

Operating Cash Flow

-$3.17M

Capital Expenditure

$0.00

Free Cash Flow

-$3.17M

Cash & ST Invst.

$1.34M

Total Debt

$193.00K

Biomerica Performance Analysis

Biomerica annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-05-31USD 18,871,409N/A
20232023-05-31USD 5,339,000-71.7%
20242024-05-31USD 5,415,0001.4%
20252025-05-31USD 5,311,000-1.9%
Biomerica sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31-33.1%
Q12025-08-3184.2%
Q22025-11-30-12.3%
Q32026-02-28-18.4%
Biomerica annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-05-31USD -2.86N/A
20232023-05-31USD -4.0441.1%
20242024-05-31USD -2.84-29.6%
20252025-05-31USD -2.16-23.9%
Biomerica sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31-135.6%
Q12025-08-31101.9%
Q22025-11-30-15100.0%
Q32026-02-282.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$987.00K

-11.8%

Gross Profit

-$44.00K

-331.6%

Gross Margin

-4.46%

N/A

Market Cap

$4.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$90.71K

N/A

Employees

54

N/A

Net Income

-$1.31M

-12.8%

EBITDA

-$1.20M

-12.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$1.34M

-56.3%

Total Debt

$193.00K

-64.5%

Accounts Receivable

$941.00K

-25.8%

Inventory

$1.65M

-0.6%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$193.00K

-44.9%

Return on Assets

-85.57%

N/A

Return on Invested Capital

-1.61%

N/A

Free Cash Flow

-$1.29M

-22.7%

Operating Cash Flow

-$1.25M

-19.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HSCSHeartSciences Inc.
$2.39-2.05%
ALZNAlzamend Neuro Inc
$1.33+5.56%
PTHLPheton Holdings Ltd Class A Ordinary Shares
$0.28-5.73%
SINTSintx Technologies, Inc.
$1.40-7.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About BMRA

What is the current price of Biomerica?

Biomerica is trading at $1.59 per share.

What is the 52-week range for Biomerica?

Over the past 52 weeks, Biomerica has traded between $1.57 and $4.60.

How much debt does Biomerica have?

As of the most recent reporting period, Biomerica reported total debt of $193.00K.

How much cash does Biomerica have on hand?

Biomerica reported $1.34M in cash and cash equivalents in its most recent financial results.

What is Biomerica’s dividend yield?

Biomerica does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services